Immunology

ImmuneRegen establishes research entity in Singapore

Published in Cancer Weekly, April 27th, 2004

IR BioSciences Holdings, Inc., (IRBH), owner of biotechnology research and development company ImmuneRegen BioSciences, Inc., has established a research entity in Singapore and has created IMM BioSciences Asia, Ltd.

IR BioSciences Holdings, Inc., will license the use of its proprietary compound Homspera through this new entity for studies on the compound's efficacy in potentially treating adverse effects of cancer, cigarette smoking, influenza, SARS/Avian Flu, and HIV, among others.

The future studies are expected to be held at research labs located at Biopolis, a center for biomedical sciences located in close proximity to the National University of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry